ClinicalTrials.gg
RecruitingNCT07232615Updated Nov 18, 2025

A Planned Study at Multiple Sites is Being Done to Compare the Results of Two Types of Trifocal Toric Intraocular Lenses Used in Cataract Surgery

An interventional study of Optiflex TRIO Intraocular Lens and AcrySof® IQ PanOptix® in Presbyopia Correction, Astigmatism and Cataract, sponsored by Biotech Healthcare Holding Gmbh. Recruiting at 6 sites in 3 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Biotech Healthcare Holding Gmbh · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Nov 2021, registered Nov 2025).
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Astigmatism with a site in Germany — 3 open to participants now, 3 under way, none of them phase 3. Astigmatism · Germany.

Planned enrollment
3rd of 10
138 · median 42
Started
2021
with 3 others
No phase
8 of 13
2 open now
Registered
13th of 13
by date
Lead sponsor
2 of 13
Biotech Healthcare Holding Gmbh

Among the 13 studies in Astigmatism with a site in Germany, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2021, is one of 8 with no phase, and was the 13th registered.

Astigmatism

418 studies on the registry are indexed under Astigmatism; 51 are open to participants now.

Browse Astigmatism studies →

Open to participants now

3 of the 13 studies in Astigmatism with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 32 Astigmatism studies recruiting now, 12 (38%) set no upper age limit and 15 (47%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Astigmatism with a site in Germany, or all of them as a file.
02

Study summary

To evaluate the clinical outcomes and patient satisfaction of two commercially available trifocal toric intraocular lenses Primary Objective: To compare the distance-corrected intermediate visual acuity between the two trifocal toric intraocular lenses. Secondary Objectives: To assess and compare the safety of two trifocal toric intraocular lenses.

Read the detailed description

Trifocal lenses are part of the premium range of refractive-diffractive trifocal IOLs with advanced aspheric optics for excellent visual outcomes. They are single piece, posterior chamber foldable intraocular lenses. The optic is refractive-diffractive trifocal with the anterior surface being aspheric and the posterior surface with a square edge design. The lens is designed to provide all near, distance and intermediate vision and thereby reduce spectacle dependency. Toric version of trifocal intraocular lens is intended to correct astigmatism.

03

Conditions studied

  • Presbyopia Correction
  • Astigmatism
  • Cataract
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of patient >21 Years
  2. Patient diagnosed with cataract.
  3. Patient must have preoperative regular corneal astigmatism between 0.75 to 4.5 D as per corneal topography or keratometry
  4. Calculated IOL power is within the range of IOLs.
  5. Patient willing to sign inform consent form.
  6. Clear intraocular media other than cataract.
  7. Female participants of must be willing to ensure that they use effective during the study.

Exclusion criteria

Exclusion Criteria:

  1. Previous intraocular or corneal surgery.
  2. Traumatic cataract
  3. Pregnancy (as stated by patient) or lactation.
  4. Concurrent participation in another drug or device investigation.
  5. Irregular astigmatism.
  6. Patient receiving chlorquine treatment.
  7. Subjects with any systemic disease that could increase operative risk or confound the outcome.
  8. Active ocular disease in the operative eye other than cataract.
  9. Vulnerable subjects as defined in section 12.3.9.
  10. Corneal Astigmatism > 4.5 D
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Optiflex TRIO (Biotech Europe Meditech Inc. Ltd.)

    Patients will be implanted with Optiflex TRIO (Biotech Europe Meditech Inc. Ltd.) IOL based on randomization

    Device: Optiflex TRIO Intraocular Lens

  • Active comparator
    AcrySof® IQ PanOptix® (Alcon Laboratories, Inc.)

    Patients will be implanted with AcrySof® IQ PanOptix® (Alcon Laboratories, Inc.) based on randomization

    Device: AcrySof® IQ PanOptix®

Interventions

  • DeviceOptiflex TRIO Intraocular Lens

    The patients will be implanted with Optiflex TRIO IOL at this arm based on randomization. Trifocal lenses are part of the premium range of refractive-diffractive trifocal IOLs with advanced aspheric optics for excellent visual outcomes. They are single piece, posterior chamber foldable intraocular lenses. The optic is refractive-diffractive trifocal Toric with the anterior surface being aspheric and the posterior surface with a square edge design. The lens is designed to provide all near, distance and intermediate vision and thereby reduce spectacle dependency. Toric version of trifocal intraocular lens is intended to correct astigmatism

  • DeviceAcrySof® IQ PanOptix®

    The patients will be implanted with AcrySof® IQ PanOptix® at this arm based on randomization. Trifocal lenses are part of the premium range of refractive-diffractive trifocal IOLs with advanced aspheric optics for excellent visual outcomes. They are single piece, posterior chamber foldable intraocular lenses. The optic is diffractive trifocal with the anterior surface being aspheric and the posterior surface with a toric component. The lens is designed to provide all near, distance and intermediate vision and thereby reduce spectacle dependency. Toric version of trifocal intraocular lens is intended to correct astigmatism.

06

What researchers measure

Primary outcomes

  1. Binocular distance corrected intermediate visual acuity (BCIDVA)

    The primary effectiveness endpoint is binocular distance corrected intermediate visual acuity (BCIDVA) at 70 cms at 6 months postoperative, with a target of equivalency between the two IOLs.

    Time frame: 6 months

07

Study locations

5 of 6 sites recruiting
  • Internationale Innovative Ophthalmochirurgie GbR
    Düsseldorf, North Rhine-Westphalia 40212, Germany
    Recruiting
    • Clinical Study Coordinator, optometrist · Contactm.kirca@augenchirurgie.clinic · 0049 0211 6006600
    • Dr. Detlev Breyer, Cataract & Refractive Surgeon · Principal investigator
    • Kristin Lena Arzt, MD, FEBO · Sub investigator
  • Augentagesklinik
    Greven, North Rhine-Westphalia 48268, Germany
    Recruiting
    • Edda Clinical Study Coordinator, Optometrist · Contact0049 0800 3 100 900
    • Dr. Karen Sophie Glandorf, MD · Principal investigator
    • Elisabeth Bari-Kacik, Specialist Ophthalmologist · Sub investigator
  • Augentagesklinik
    Rheine, North Rhine-Westphalia 48429, Germany
    Recruiting
    • Clinical Study Coordinator, optometrist · Contacta.gerling@precise.vision · 0049 0 800 3 100 900
    • Dr. Florian Kretz, MD, FEBO · Principal investigator
    • David Beckers, MD · Sub investigator
    • Lena Beckers, MD · Sub investigator
    • Jil-Catherine Große-Volksbeck, MD · Sub investigator
    • Frauke Jürgens, Specialist Ophthalmologist · Sub investigator
  • Netradhama Superspeciality Eye Hospital
    Bangalore, Karnatak 560082, India
    Not yet recruiting
    • Aditi chowdhary, Optometrist · Contactresearch@nethradhama.org · +9196935 10981
    • Dr. Sri Ganesh, Cataract & Refractive Surgeon · Principal investigator
  • Dr. Agarwal Eye Hospital
    Chennai, Tamil Nadu 600018, India
    Recruiting
    • Shalini Ramasamy, Optometrist · Contactshalini.r@dragarwal.com · +91 82202 87800
    • Dr. Ashvin Agarwal, M.S. (Opthalmology) · Principal investigator
  • Hospital Arruzafa
    Córdoba, Córdoba 14012, Spain
    Recruiting
    • David Cerdan Clinical Study Coordinator, Optometrist · Contactdcerdan@hospitalarruzafa.com · 0034 957 40 10 40
    • Antonio Cano Ortiz, Cataract & Refractive Surgeon · Principal investigator
    • Alberto Villarubia Cuadrado · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

Of 106 industry-sponsored interventional studies with no phase under Astigmatism, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 19. This study's planned 61 months is above that.

Counting every sponsor, half of 183 studies reached it within 12 months; a quarter within 4 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Nov 22, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07232615
Lead sponsor
Biotech Healthcare Holding Gmbh
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Nov 22, 2021
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 18, 2025

Study contacts

BHARGAV D JOSHI, M.Sc.
Contact
bhargav.joshi@biotechhealthcare.com
+917966823000 ext. 203

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion